DHA and X-Linked Retinitis Pigmentosa

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

78 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2014-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose:

Retinitis pigmentosa (RP) is characterized by progressive loss of visual function due to specific genetic mutations. This trial is focused on patients with one of the most severe forms of the disease, X-linked inherited RP (XLRP). This disease is characterized by early onset (typically loss of night vision as a child) followed by loss of peripheral vision as a teenager and young adult. There is no male-to-male transmission of the disease in the family.

There is no cure for RP and treatment options are limited. Two clinical trials have not found a benefit from nutritional supplementation with the long-chain polyunsaturated fatty acid, docosahexaenoic acid (DHA), at low daily doses although there is evidence that it slows disease progression in certain instances. In this clinical trial, we propose that a high dose nutritional DHA supplement will slow the loss of visual function and preserve usable vision in patients with XLRP.

This study is a 4-year placebo-controlled randomized clinical trial meaning that patients have a 50-50 chance of receiving placebo or experimental treatment. A total of 66 patients will be enrolled; 33 will receive placebo and 33 will receive the treatment. Entry criteria include diagnosis of XLRP by an ophthalmologist, age 7 to 32 years, male, sufficient visual function such that disease progression can be followed for the entire duration of the trial, and a willingness to visit the testing site (Dallas, TX) once a year.

Annual visual function testing includes ETDRS visual acuity, full-field and multifocal electroretinography (ERG), static peripheral visual fields, and fundus photography. Cone ERG function is the primary outcome measure.

Funding Source - FDA, Foundation Fighting Blindness, DSM Nutritionals

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa

NCT00004827

Retinitis Pigmentosa

COMPLETED NA

Randomized Trial of DHA for Retinitis Pigmentosa Patients Receiving Vitamin A

NCT00000116

Retinitis Pigmentosa

COMPLETED PHASE3

Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy

NCT00060749

Macular Degeneration

COMPLETED PHASE1

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455

Retinitis Pigmentosa

COMPLETED PHASE1

Study of Dietary N-3 Fatty Acids in Patients With Retinitis Pigmentosa and Usher Syndrome

NCT00004345

Usher Syndrome Retinitis Pigmentosa

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Location \& Contact Information:

Retina Foundation of the Southwest, 9600 N. Central Expressway, Suite 200, Dallas, TX 75231 Contact: Dr. D. Hoffman ([email protected]) or Dr. D. Birch ([email protected]).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinitis Pigmentosa X-linked Genetic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1.

Oral Docosahexaenoic acid, dosage based on body weight

Group Type EXPERIMENTAL

docosahexaenoic acid OR corn/soy oil placebo

Intervention Type DRUG

daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial

2

corn/soy oil placebo; oil not containing DHA...dosage based on body weight

Group Type PLACEBO_COMPARATOR

docosahexaenoic acid OR corn/soy oil placebo

Intervention Type DRUG

daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

docosahexaenoic acid OR corn/soy oil placebo

daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

DHA; omega-3 fatty acid OR RANDOMIZED TO corn/soy oil placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of RP by a retinal specialist
* Clinical diagnosis consistent with X-linked inheritance
* Enrolling minors and young adults (early onset of X-linked disease; ages 7 to 32)
* Measurable cone ERG responses --patients with less than 0.64 microvolt response to 31-Hz flicker will be excluded as they are more likely to become undetectable during the study
* Both eyes must meet entry criteria as both will be tested (i.e., no cataracts requiring surgery or retinal detachments).
* Media clarity sufficient for fundus photography
* Able to return to study site at yearly intervals
* Willing to supply blood samples at 6-month intervals
* Judiciously take the placebo or DHA supplement for the 4-year study duration
* Patient/parent/guardian understands and signs consent form.

Exclusion Criteria

* Excessive fish consumption (e.g., cold water fish such as salmon, tuna, sardines) and/or fish oil supplementation (or other oil containing DHA)
* Baseline RBC-DHA levels showing evidence of supplementation (a typical level of RBC-DHA in normals is about 3.8%)
* Chronic metabolic disease that may interfere with fatty acid metabolism or require anti-coagulant medication

No ethnic or racial groups will be excluded.

Minimum Eligible Age

7 Years

Maximum Eligible Age

32 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No